SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-058990
Filing Date
2023-03-03
Accepted
2023-03-03 07:31:32
Documents
13
Period of Report
2023-03-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d478993d8k.htm   iXBRL 8-K 29830
2 EX-10.1 d478993dex101.htm EX-10.1 91168
  Complete submission text file 0001193125-23-058990.txt   264295

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA srpt-20230302.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE srpt-20230302_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srpt-20230302_pre.xml EX-101.PRE 10811
7 EXTRACTED XBRL INSTANCE DOCUMENT d478993d8k_htm.xml XML 3230
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

IRS No.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14895 | Film No.: 23701639
SIC: 2834 Pharmaceutical Preparations